Industry News
Biotechnology Industry News
Young inflammatory disease biotech…
Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an investigational DPP-1 inhibitor from Fosun Pharma.
IO Biotech’s cancer vaccine has…
IO Biotech’s cancer vaccine has “narrowly” failed to beat Keytruda in a phase 3 melanoma trial, but the company remains hopeful of a path to approval.
Novartis may have abandoned one of…
Novartis may have abandoned one of its Sjögren's syndrome assets this year, but it now looks like the pharma has a winner on its hands.
The FDA has denied Stealth…
The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease hanging in limbo.
After the recent approval and…
After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. The Bay Area company has dropped two early-stage cancer candidates and a Novo Nordisk-partnered combination treatment for
Bicycle Therapeutics is reducing…
Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. The layoffs, which are part of a push to cut spending by 30%, follow Genentech’s termination of an oncology
Ipsen has backed out of a $900…
Ipsen has backed out of a $900 million biobucks deal for Sutro Biopharma’s ROR1-directed antibody-drug conjugate.
Longevity company Altos Labs has…
Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics co-founder and CEO Joan Mannick, Ph.D., is now senior vice president, chief medical officer and head
An impressive array of Big Pharma…
An impressive array of Big Pharma backers lined up to help ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic.
Eli Lilly is pivoting its pain…
Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase portfolio.
Minghui has secured $131 million…
Minghui has secured $131 million for what the company describes as a “pre-IPO” round to fuel the potential launch of its eye drug in China as well as various clinical-stage oncology and immunology assets.
Gilead has returned the rights to…
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was deprioritized earlier this year.
Keros has shaken up its leadership…
Keros has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy asset.
As other pharmas drop next-gen…
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average of 27.3 pounds in the first of two pivotal trials, queuing up plans for a
The Trump administration has…
The Trump administration has broken the law by withholding funds that Congress had allocated to the National Institutes of Health (NIH), according to the Government Accountability Office (GAO).
Alltrna, the preclinical Flagship…
Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic.
Contineum Therapeutics has pumped…
Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.
Kaken Pharmaceutical is paying $16…
Kaken Pharmaceutical is paying $16 million upfront for the Japanese rights to Astria Therapeutics’ phase 3-stage hereditary angioedema drug.
Terns Pharmaceuticals is planning…
Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential deals for assets including a midphase oral obesity prospect.
Novo Nordisk has abandoned another…
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that coincides with disappointing obesity sales and a leadership shake-up.